RxDoctor Payments Data

Rian Montgomery, MD

Internal Medicine · Birmingham, ALNPI 1982628947

Payments from drug & device makers

$3,205in general payments, 2019–2025

Across 186 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$685
  • GSK$451
  • Pfizer$348
  • Dexcom, Inc.$293
  • Amgen$236
  • Lilly USA, LLC$192
  • plus $1000 from 16 others

What the payments were for

  • Food & beverage$3,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,205 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$79,473
Medicare patients
166
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin149$167,891
OzempicSemaglutide118$146,717
EliquisApixaban105$109,593
TrulicityDulaglutide76$84,021
MyrbetriqMirabegron43$33,445
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,369
TradjentaLinagliptin43$27,369
LinzessLinaclotide22$22,675
JanuviaSitagliptin Phosphate21$20,539
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$18,123
FarxigaDapagliflozin Propanediol17$14,910
EntrestoSacubitril/Valsartan11$14,301
XareltoRivaroxaban18$13,640
Breo ElliptaFluticasone/Vilanterol21$11,202
Spiriva RespimatTiotropium Bromide15$10,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$71$206,224207 claims
Novo NordiskOzempic$685$146,717118 claims
PfizerEliquis$348$109,593105 claims
Lilly USA, LLCTrulicity$192$84,02176 claims
GSKTrelegy Ellipta, Breo Ellipta$451$41,57056 claims
Astellas Pharma US IncMyrbetriq$156$33,44543 claims
AbbVieLinzess$66$22,67522 claims
MerckJanuvia$17$20,53921 claims
AstraZenecaFarxiga, Symbicort$39$18,17129 claims
NovartisEntresto$85$14,30111 claims
Johnson & JohnsonXarelto$130$13,64018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →